Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)

Volume 15, 10 Issues, 2016

Download PDF Flyer

CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 107th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.628
5 - Year: 3.148

Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting

CNS & Neurological Disorders - Drug Targets, 13(2): 299-304.

Author(s): Nasimudeen R. Jabir, Mohammad A. Kamal, Adel Mohammad Abuzenadah, Siew Hua Gan, Mohammed Nabil Alama, Saleh S. Baeesa and Shams Tabrez.

Affiliation: King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.


Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two devastating diseases that are currently incurable. Epidemiological, clinical and pathological evidence has confirmed the co-existence of these two disorders. Moreover, there has been promising progress made in the identification of the pathological linkage between T2DM and AD in the last decade. Hence, developing common treatment strategies for these diseases is important. Currently, enzyme targeting is a potential strategy to cure many diseases. In this communication, we tried to summarize the single enzymetargeted therapeutic approach for the treatment of AD and T2DM. This field of research continues to be active and progressive in identifying many promising enzymes that are involved in both diseases. Based on this review article, we also believe that enzyme inhibition is a promising and reliable strategy for the treatment of many incurable diseases. In the future, we expect that the scientific community will be able to develop common enzyme inhibitors for the treatment of both AD and T2DM.


Alzheimer’s disease, diabetes, enzymes, drug therapy, endocrine disorders.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 2
First Page: 299
Last Page: 304
Page Count: 6
DOI: 10.2174/18715273113126660145

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science